Pharmaceutical intermediates
Cabozantinib S-malate Intermediates
3 pharmaceutical intermediates for Cabozantinib S-malate. Indication: Pancreatic neuroendocrine tumors; Renal cell carcinoma; Hepatocellular carcinoma; Thyroid cancer; Neuroendocrine carcinoma.
About Cabozantinib S-malate
- Originator
- Exelixis Inc
- Indication
- Pancreatic neuroendocrine tumors; Renal cell carcinoma; Hepatocellular carcinoma; Thyroid cancer; Neuroendocrine carcinoma
- Approved Date
- 11/29/2012
- DS/DP
- 08/14/2026
Available intermediates
3 intermediates currently listed for Cabozantinib S-malate. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 4-Hydroxy-6,7-dimethoxyqunioline | 13425-93-9 | / | / |
| 4-((6,7-Dimethoxyquinolin -4-yl)oxy)aniline | 190728-25-7 | / | / |
| 1-(4-Fluorophenylcarbamoyl)cyclopropanecarboxylic acid | 849217-48-7 | / | / |
Building toward Cabozantinib S-malate?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →